News
Novo Nordisk Inks A Major Obesity Deal
Digest more
Novo Nordisk A/S’s decision to stop making insulin pens will narrow treatment options for children with diabetes unless ...
Novo Nordisk A/S is a biopharma company that has specialized in the diabetes market for a long time. This is an attractive market to be in, as there are significant unmet medical needs since the ...
Novo Nordisk has reduced its sales and profits forecasts for 2025 due to lower-than-expected demand in the US for blockbuster weight loss and diabetes drugs, though shares in the company were ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback